VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

16 May 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

09 May 2024 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

02 May 2024 13:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

11 Mar 2024 04:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

07 Mar 2024 05:00:19 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

06 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

04 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

27 Feb 2024 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

22 Feb 2024 04:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

21 Nov 2023 13:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

10 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

09 Nov 2023 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

06 Nov 2023 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis

09 Oct 2023 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

30 Aug 2023 13:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress

10 Aug 2023 13:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023

03 Aug 2023 13:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference

02 Aug 2023 13:06:38 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor

14 Jun 2023 04:00:00 By Nasdaq GlobeNewswire